Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBT Margin (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of EBT Margin data on record, last reported at 1093.33% in Q4 2025.

  • For Q4 2025, EBT Margin changed N/A year-over-year to 1093.33%; the TTM value through Dec 2025 reached 181.28%, changed N/A, while the annual FY2025 figure was 142.91%, 719291.0% down from the prior year.
  • EBT Margin reached 1093.33% in Q4 2025 per RCUS's latest filing, down from 400.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 126.03% in Q3 2024 and bottomed at 1093.33% in Q4 2025.
  • Average EBT Margin over 5 years is 358.98%, with a median of 256.62% recorded in 2023.
  • The widest YoY moves for EBT Margin: up 177268bps in 2021, down -82700bps in 2021.
  • A 5-year view of EBT Margin shows it stood at 79.39% in 2021, then tumbled by -351bps to 199.08% in 2022, then decreased by -30bps to 258.06% in 2023, then surged by 149bps to 126.03% in 2024, then plummeted by -968bps to 1093.33% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 1093.33% in Q4 2025, 400.0% in Q1 2025, and 126.03% in Q3 2024.